Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
- PMID: 35924080
- PMCID: PMC9340394
- DOI: 10.1177/17562848221115312
Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
Abstract
Patients with inflammatory bowel disease (IBD) often have other immune-mediated inflammatory diseases (IMIDs), and the prevalence of any IMID is higher in IBD patients than in the general population. IBD and other IMIDs involve alterations in innate and adaptive immune responses. Their co-occurrence depends on shared immune and inflammatory processes, pathogenic mechanisms, and genetic and environmental risk factors, including drugs, especially tumor necrosis factor inhibitors. The more common IMIDs associated with IBD have been widely described, so this review focuses on the less frequent associations. The IMIDs discussed here are skin disorders (psoriasis, atopic dermatitis, vitiligo, epidermolysis bullosa acquisita, cutaneous polyarteritis nodosa, and hidradenitis suppurativa), hepato-pancreatic diseases (autoimmune hepatitis, granulomatous hepatitis, and autoimmune pancreatitis), endocrine diseases (autoimmune thyroid diseases, and type 1 diabetes mellitus), multiple sclerosis, and respiratory diseases (asthma, bronchiectasis, and interstitial pneumonia). The early detection of IMIDs in IBD patients is important to prevent their deleterious clinical course and limit their psychological impact. Care for IBD patients with IMIDs should be multispecialist, with a single therapeutic strategy instead of treating each disease separately.
Keywords: Crohn’s disease; atopic dermatitis; hidradenitis suppurativa; immune-mediated inflammatory disease; inflammatory bowel disease; multiple sclerosis; psoriasis; ulcerative colitis.
© The Author(s), 2022.
Conflict of interest statement
Competing interests: The authors declare that there is no conflict of interest.
Similar articles
-
Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2704-2712.e3. doi: 10.1016/j.cgh.2019.03.040. Epub 2019 Mar 29. Clin Gastroenterol Hepatol. 2019. PMID: 30936024
-
Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study.J Clin Med. 2024 Feb 9;13(4):1019. doi: 10.3390/jcm13041019. J Clin Med. 2024. PMID: 38398332 Free PMC article.
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294387 Free PMC article.
-
Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases.Inflamm Bowel Dis. 2021 May 17;27(6):927-939. doi: 10.1093/ibd/izaa167. Inflamm Bowel Dis. 2021. PMID: 32628745
-
Immune-mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitis.JGH Open. 2022 Jan 20;6(2):100-111. doi: 10.1002/jgh3.12706. eCollection 2022 Feb. JGH Open. 2022. PMID: 35155819 Free PMC article. Review.
Cited by
-
Conundrum for Psoriasis and Thyroid Involvement.Int J Mol Sci. 2023 Mar 3;24(5):4894. doi: 10.3390/ijms24054894. Int J Mol Sci. 2023. PMID: 36902323 Free PMC article. Review.
-
CXCL13: a common target for immune-mediated inflammatory diseases.Clin Exp Med. 2024 Oct 24;24(1):244. doi: 10.1007/s10238-024-01508-8. Clin Exp Med. 2024. PMID: 39443356 Free PMC article. Review.
-
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.Saudi J Gastroenterol. 2025 Mar 1;31(2):59-67. doi: 10.4103/sjg.sjg_7_24. Epub 2024 Apr 10. Saudi J Gastroenterol. 2025. PMID: 38597337 Free PMC article.
-
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey.J Clin Med. 2024 Mar 23;13(7):1857. doi: 10.3390/jcm13071857. J Clin Med. 2024. PMID: 38610623 Free PMC article.
-
Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.Front Neurol. 2025 Feb 5;16:1530438. doi: 10.3389/fneur.2025.1530438. eCollection 2025. Front Neurol. 2025. PMID: 39974366 Free PMC article.
References
-
- Hedin CRH, Vavricka SR, Stagg AJ, et al.. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 2019; 13: 541–554. - PubMed
-
- Tavares Da, Silva F, De Keyser F, Lambert PH, et al.. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013; 31: 1870–1876. - PubMed
-
- Brophy S, Pavy S, Lewis P, et al.. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001; 28: 2667–2673. - PubMed
Publication types
LinkOut - more resources
Full Text Sources